• Skip to main content
  • Skip to footer

Akari Therapeutics

AN INNOVATIVE TARGETED ONCOLOGY COMPANY BUILT ON NEXT GENERATION ANTIBODY-DRUG CONJUGATES (ADC) AND A NOVEL DISCOVERY ENGINE

Menu
  • HOME
  • ABOUT
    • Close
    • COMPANY OVERVIEW
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • CEO CORNER
    • SCIENTIFIC ADVISORY BOARD
  • AREAS OF FOCUS
    • Close
    • PIPELINE
    • POSTERS & PUBLICATIONS
    • LEGACY PIPELINE ASSETS
  • INVESTOR RELATIONS
    • Close
    • OVERVIEW
    • GENERAL MEETING
    • CORPORATE GOVERNANCE
      • Close
      • GOVERNANCE OVERVIEW
      • BOARD OF DIRECTORS
      • MANAGEMENT
      • COMMITTEE COMPOSITION
    • FINANCIAL INFORMATION
      • Close
      • SEC FILINGS
      • ANNUAL REPORTS
    • NEWS & PRESENTATIONS
      • Close
      • PRESS RELEASES
      • PRESENTATIONS
    • ANALYST COVERAGE
    • STOCK INFORMATION
      • Close
      • STOCK QUOTE & CHART
      • HISTORIC PRICE LOOKUP
    • EMAIL ALERTS
  • PRESS
    • Close
    • PRESS RELEASES
    • STORIES
  • CONTACT US

Akari TX / January 31, 2017

Akari Therapeutics to Attend Upcoming Investor Conferences in February

NEW YORK and LONDON, January 31st, 2017

Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that senior management will attend and host meetings at two upcoming conferences.

• Canaccord Genuity 2017 Rare Disease, Biopharma One-on-One Day on Tuesday, February 7, 2017 in New York, NY
• Leerink Partners 6th Annual Global Healthcare Conference on February 16, 2017 in New York, NY

Click here to see full release

Filed Under: Press Release

Footer

Follow Us

Terms of Use
Privacy Statement
Contact Us

Akari TX

Copyright © 2025 · Akari Therapeutics · Site Designed by Polus Digital, Inc.